Targeted Radiotherapy

3B Pharmaceuticals (3BP) is a leading developer of targeted molecular radiopharmaceuticals focusing on cancer indications with high medical need. The focus of our drug development programs is a theragnostic approach using diagnostic imaging to identify patients who are likely responders to radiopharmaceutical therapy. 3BP has built a unique technology platform for the efficient discovery and validation of cancer radiopharmaceuticals.

Three of 3BP’s development programs for radiopharmaceutical therapies are being developed with pharmaceutical industry partners. Some partners have licensed the exclusive world-wide rights, while 3BP has retained development and commercialization rights in some of the programs for particular geographic areas. Clinical development in specific geographies and for certain focused diagnostic and therapeutic indications will be sponsored by 3BP.